Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10646575 Heterocyclic degronimers for target protein degradation

Patent 10646575 was granted and assigned to C4 Therapeutics on May, 2020 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

C4 Therapeutics

Current Assignee

C4 Therapeutics

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

10646575

Date of Patent

May 12, 2020

Patent Application Number

16186339

Date Filed

November 9, 2018

Patent Citations

‌

US Patent 10414755 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof

Patent Citations Received

‌

US Patent 12091397 Dihydroquinolinones for medical treatment

‌

US Patent 11524949 Degraders and Degrons for targeted protein degradation

‌

US Patent 12076405 Heterocyclic degronimers for target protein degradation

‌

US Patent 11459335 N/O-linked Degrons and Degronimers for protein degradation

‌

US Patent 11560381 Compounds and uses thereof

‌

US Patent 10905768 Heterocyclic degronimers for target protein degradation

‌

US Patent 11584748 Spirocyclic compounds

...

Patent Primary Examiner

‌

Alexander R Pagano

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10646575 Heterocyclic degronimers for target protein degradation

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API